Cross-sectional study assesses EuroQol-5 Dimensions performance in haematologic malignancies, indicating its reliability in some groups.
Key Points
The aim is to evaluate the reliability and validity of the EuroQol-5 Dimensions instrument in patients with haematologic malignancies.
Conducted a cross-sectional observational study
Employed EuroQol-5 Dimensions and time trade-off to assess health-related quality of life
Included 158 patients with multiple myeloma, acute leukaemia, and lymphoma
Analyzed EQ-5D performance based on internal consistency, criterion validity, and structural validity
Total utility scores were highest in acute leukaemia (0.798), lower in lymphoma (0.755), and lowest in multiple myeloma (0.693)
EQ-5D utility values were consistently higher than TTO across all groups
EQ-5D showed excellent internal consistency (Cronbach’s α=0.899) and the strongest correlation with TTO in multiple myeloma patients (r=0.538, p<0.001)
Moderate validity in acute leukaemia (r=0.386, p=0.002) and poor validity in lymphoma (r=0.230, p=0.129)
Chronic kidney failure correlated with greater TTO–EQ-5D utility discrepancy in acute leukaemia patients